Followers | 145 |
Posts | 27714 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, February 28, 2014 11:47:37 AM
Friday 28 February 2014
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has priced an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $10.50 per share. Gross proceeds to Compugen are expected to be $63 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. Compugen has granted the underwriters a thirty (30) day option to purchase up to 900,000 additional ordinary shares.
Recent CGEN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/13/2024 11:00:22 AM
- Compugen to Present at Single Cell Genomics 2024 Conference • PR Newswire (US) • 09/09/2024 11:00:00 AM
- Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 08/29/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/06/2024 11:00:42 AM
- Compugen Reports Second Quarter 2024 Results • PR Newswire (US) • 08/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/05/2024 11:00:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 11:00:04 AM
- Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors • PR Newswire (US) • 07/29/2024 11:00:00 AM
- Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 • PR Newswire (US) • 07/23/2024 11:00:00 AM
- Compugen to Present at Upcoming Antibody Industrial Symposium • PR Newswire (US) • 06/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 11:00:12 AM
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig • PR Newswire (US) • 05/30/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2024 11:00:07 AM
- Compugen Reports First Quarter 2024 Results • PR Newswire (US) • 05/20/2024 11:00:00 AM
- U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip • IH Market News • 05/20/2024 10:59:35 AM
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 11:02:08 AM
- Compugen Appoints David Silberman as Chief Financial Officer • PR Newswire (US) • 05/15/2024 11:00:00 AM
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Compugen to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 04/03/2024 11:00:00 AM
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:06:21 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM